A systematic comparison of methods to measure HIV-1 specific CD8 T cells

被引:96
作者
Sun, Y [1 ]
Iglesias, E [1 ]
Samri, A [1 ]
Kamkamidze, G [1 ]
Decoville, T [1 ]
Carcelain, G [1 ]
Autran, B [1 ]
机构
[1] Ctr Hosp Pitie Salpetriere, INSERM, U543, Lab Immunol Cellulaire & Tissulaire, F-75013 Paris, France
关键词
HIV-specific CD8 T cell; ELISpot assay; Cr-51 release assay; tetramer-binding assay; intracellular cytokine staining;
D O I
10.1016/S0022-1759(02)00328-9
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Several methods are now available to evaluate the frequencies of virus-specific CD8 T cells but require a systematic comparison to help at choosing the best strategy for evaluation. First, we compared the ELISpot-IFNgamma assay, intracellular IFNgamma staining and HLA class I tetramer-binding assay to quantify the HIV-specific CD8 T cells. Second, we determined the frequency of recognition of HIV antigens and evaluated whether the mode of antigen presentation might influence the results: We compared HIV antigen presentation in the same ELISpot-IFNgamma assays by using recombinant vaccinia viruses (rVvs) encoding for HIV-LAI Gag, Pol, Env, Nef, Tat and Vif proteins, or a panel of 49 synthetic 8-11 amino acid length peptides tested either individually or pooled. Third, we compared the antigens recognized by memory CTL analysis using chromium release assay (CRA) on CTL lines and by effector CD8 cell analysis using ELISpot assay. Our results show that: (1) Flow cytometry and ELISpot assay measuring IFNgamma production give the same frequency of HIV-specific CD8 T cells; (2) tetramer-binding assay detects more HIV-specific CD8 T cells than other methods; (3) pools of optimal peptides and sum frequencies of individual optimal peptides give: similar results in ELISpot assay; (4) ELISpot assays using peptides are more sensitive than those using rVV; and (5) CRA and ELISpot assay when using rVV provide a comparable profile of HIV antigen recognition by memory CTLs (CRA) and effector CTLs (ELISpot) in two thirds cases. These results have important implications for the choice of immunological methods to evaluate CD8 T cells responses to vaccines. (C) 2002 Published by Elsevier Science B.V.
引用
收藏
页码:23 / 34
页数:12
相关论文
共 23 条
[1]   Phenotypic analysis of antigen-specific T lymphocytes [J].
Altman, JD ;
Moss, PAH ;
Goulder, PJR ;
Barouch, DH ;
McHeyzerWilliams, MG ;
Bell, JI ;
McMichael, AJ ;
Davis, MM .
SCIENCE, 1996, 274 (5284) :94-96
[2]   HIV-specific CD8+ T cells produce antiviral cytokines but are impaired in cytolytic function [J].
Appay, V ;
Nixon, DF ;
Donahoe, SM ;
Gillespie, GMA ;
Dong, T ;
King, A ;
Ogg, GS ;
Spiegel, HML ;
Conlon, C ;
Spina, CA ;
Havlir, DV ;
Richman, DD ;
Waters, A ;
Easterbrook, P ;
McMichael, AJ ;
Rowland-Jones, SL .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (01) :63-75
[3]   Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood [J].
Dunbar, PR ;
Ogg, GS ;
Chen, J ;
Rust, N ;
van der Bruggen, P ;
Cerundolo, V .
CURRENT BIOLOGY, 1998, 8 (07) :413-416
[4]   Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors [J].
Gea-Banacloche, JC ;
Migueles, SA ;
Martino, L ;
Shupert, WL ;
McNeil, AC ;
Sabbaghian, MS ;
Ehler, L ;
Prussin, C ;
Stevens, R ;
Lambert, L ;
Altman, J ;
Hallahan, CW ;
de Quiros, JCLB ;
Connors, M .
JOURNAL OF IMMUNOLOGY, 2000, 165 (02) :1082-1092
[5]   A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon [J].
Goepfert, PA ;
Bansal, A ;
Edwards, BH ;
Ritter, GD ;
Tellez, I ;
McPherson, SA ;
Sabbaj, S ;
Mulligan, MJ .
JOURNAL OF VIROLOGY, 2000, 74 (21) :10249-10255
[6]   HIGH-FREQUENCY OF MEMORY AND EFFECTOR GAG SPECIFIC CYTOTOXIC LYMPHOCYTES-T IN HIV SEROPOSITIVE INDIVIDUALS [J].
GOTCH, FM ;
NIXON, DF ;
ALP, N ;
MCMICHAEL, AJ ;
BORYSIEWICZ, LK .
INTERNATIONAL IMMUNOLOGY, 1990, 2 (08) :707-712
[7]  
Gray CM, 1999, J IMMUNOL, V162, P1780
[8]  
Haas G, 1996, J IMMUNOL, V157, P4212
[9]  
HADIDA F, 1995, J IMMUNOL, V154, P4174
[10]  
HOFFENBACH A, 1989, J IMMUNOL, V142, P452